4Czock D,Aisenpreis U,Rasche FM,et al.Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus[J].Int J Clin Pharmacol Ther,2003,41 (10):492.
5Homko C,Deluzio A,Jimenez C,et al.Comparison of insulin aspart and lispro:pharmacokinetic and metabolic effects[J].Diabetes Care,2003,26(7):2 027.
6Edelman SV,Morello CM.Strategies for insulin therapy in type2 diabetes[J].South Med J,2005,98(3):363.
7Jermendy G.Evidence based therapy with insulin in diabetic patients[J].Orv Hetil,2005,146(8):341.
8UK Prospective Diabetes Study Group.Effect of intensive blood glucose control with metfomin on complication in overweight patients with type 2 diabetes(UKPDS)[J].Lancet,1998,352:854.
9Knowler WC,Barrett-Connor E,Fowles SE,et al.Diabetes Prevention Program Research Group.Reduction in the incidence of type 2 diabetes with lifestyle intevention or metfomin[J].N Engl J Med,2002,346:393.
10Kikuo Isoda,James L,Young,et al.Metformin inhibits proinflammatory responses and nuclear factor κ-B in human vascular wall cells[J].Arterioscler Thromb Vasc Biol,2006,26(3):611.
